FierceBiotechOriginal article
{"a":[{"_":"Pharvaris' latest phase 3 win builds case for HAE drug with FDA verdict pending","$":{"href":"/biotech/pharvaris-builds-case-hae-drug-awaiting-fda-verdict-another-phase-3-win","hreflang":"en"}}]}
Phase 3positivedeucrictibantPositive
AI Analysis
Summary
Pharvaris announced positive results from a second phase 3 study of deucrictibant for hereditary angioedema treatment, strengthening the case for FDA approval which is currently pending.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Second phase 3 study success for deucrictibant in hereditary angioedema
Importance:7/10
Sentiment:
0.75
Phase 3hereditary angioedemaFDA pendingdeucrictibant
Related Companies
Read the original article
Published by FierceBiotech on September 8, 2026 9:29 AM